The direct causes of Alzheimer's disease continues to elude the scientific community, which makes creating treatments for it exceedingly difficult. We have seen a number of high-profile failures lately, and now Baxter International can be added to that list. Shares were down slightly, as drug Gammagard failed to preserve or reduce the decline of cognitive function in patients during phase 3 trials.

In this video, health-care analyst David Williamson discusses what's next for Baxter and other promising drugs to treat Alzheimer's that investors need to have on their radars.

Follow David on Twitter: @MotleyDavid.

David Williamson owns shares of Pfizer. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.